These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23635316)

  • 21. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray.
    Liu D; He J; Yuan Z; Wang S; Peng R; Shi Y; Teng X; Qin T
    Med Oncol; 2012 Jun; 29(2):401-5. PubMed ID: 21264531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.
    He ZY; Wu SG; Zhou J; Li FY; Lin Q; Lin HX; Sun JY
    PLoS One; 2015; 10(3):e0119105. PubMed ID: 25781605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
    Svoboda M; Sana J; Redova M; Navratil J; Palacova M; Fabian P; Slaby O; Vyzula R
    Diagn Pathol; 2012 Mar; 7():31. PubMed ID: 22439831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel prognostic markers for patients with triple-negative breast cancer.
    Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
    Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinicopathologic features and prognosis of triple negative breast cancer].
    Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
    Montagna E; Maisonneuve P; Rotmensz N; Cancello G; Iorfida M; Balduzzi A; Galimberti V; Veronesi P; Luini A; Pruneri G; Bottiglieri L; Mastropasqua MG; Goldhirsch A; Viale G; Colleoni M
    Clin Breast Cancer; 2013 Feb; 13(1):31-9. PubMed ID: 23098574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer.
    Wu MQ; Hu P; Gao J; Wei WD; Xiao XS; Tang HL; Li X; Ge QD; Jia WH; Liu RB; Xie XM
    Asian Pac J Cancer Prev; 2013; 14(1):287-92. PubMed ID: 23534739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
    Zhao P; Lu Y; Jiang X; Li X
    Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
    Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
    Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
    Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
    PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer.
    Jääskeläinen A; Jukkola A; Haapasaari KM; Auvinen P; Soini Y; Karihtala P
    Anticancer Res; 2019 Nov; 39(11):5879-5890. PubMed ID: 31704812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TMPRSS4 as a poor prognostic factor for triple-negative breast cancer.
    Cheng D; Kong H; Li Y
    Int J Mol Sci; 2013 Jul; 14(7):14659-68. PubMed ID: 23857060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
    El-Gendi SM; Mostafa MF
    Pathol Oncol Res; 2016 Jul; 22(3):461-70. PubMed ID: 26597806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer.
    Zagouri F; Bago-Horvath Z; Rössler F; Brandstetter A; Bartsch R; Papadimitriou CA; Dimitrakakis C; Tsigginou A; Papaspyrou I; Giannos A; Dimopoulos MA; Filipits M
    Br J Cancer; 2013 Mar; 108(5):1100-5. PubMed ID: 23422757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
    Morgan E; Suresh A; Ganju A; Stover DG; Wesolowski R; Sardesai S; Noonan A; Reinbolt R; VanDeusen J; Williams N; Cherian MA; Li Z; Young G; Palettas M; Stephens J; Liu J; Luff A; Ramaswamy B; Lustberg M
    World J Surg Oncol; 2020 Jan; 18(1):11. PubMed ID: 31937323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.